SCHEMBL25357966

SCHEMBL25357966

CC(=O)Nc1ccc(C(C)=O)c(OC(=O)c2ccc(N(C)CCOCCOCCOCCOCCOCCOCc3ccccc3)cc2)c1[N+](=O)[O-]

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ LMNA P02545 2/20 0.40
▸ CYP19A1 P11511 1/20 0.39
▸ BRD4 O60885 7/20 0.37
▸ KIT P10721 2/20 0.36
▸ FLT3 P36888 2/20 0.35
▸ MAPT P10636 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ ACHE P22303 1/20 0.33
▸ NT5E P21589 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31191034 0.87 CRHBP (0.39) ALDH1A1HTTLMNACYP19A1BRD4
SCHEMBL31290998 0.87 CRHBP (0.39) ALDH1A1HTTLMNACYP19A1BRD4
SCHEMBL25357971 0.84 CYP19A1 (0.39) ALDH1A1HTTLMNACYP19A1BRD4
SCHEMBL25355430 0.83 ALDH1A1 (0.40) ALDH1A1HTTLMNACYP19A1BRD4
SCHEMBL31191011 0.83 ALDH1A1 (0.40) ALDH1A1HTTLMNACYP19A1BRD4
SCHEMBL8511034 0.80 MAPT (0.49) ALDH1A1LMNAMAPTHPGDNPSR1
SCHEMBL16875669 0.80 MDM2 (0.42) ALDH1A1HTTCYP19A1MAPTHPGD
SCHEMBL18973787 0.76 CYP19A1 (0.41) ALDH1A1LMNACYP19A1BRD4MAPT
SCHEMBL25359757 0.75 CYP19A1 (0.58) CYP19A1BRD4MAPTCYP2C9CYP2C19
SCHEMBL25359144 0.70 ALDH1A1 (0.48) ALDH1A1HTTLMNAKITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161459-A1 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2025-05-22 — — US disclosed
WO-2025038963-A1 OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS ADARX PHARMACEUTICALS, INC. (US) 2025-02-20 — — WO disclosed
EP-4475837-A2 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2024-12-18 — — EP disclosed
WO-2024220930-A2 MAPT-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF ADARX PHARMACEUTICALS, INC. (US) 2024-10-24 — — WO disclosed
WO-2023154896-A2 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF ADARX PHARMACEUTICALS, INC. (US) 2023-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161459-A1 TRKB LIGAND CONJUGATED COMPOUNDS AND USES THEREOF NTRK2, NTRK1, BDNF ALDH1A1 1653/4885HTT 98/4885LMNA 2612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback